A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan.

Azad A Haleem, Azhar Alsaqee, Lana A Dizayi, Sasan L Hanna, Abbas A Rabaty, Serdar Pedawi, Aso F Salih

Abstract read

In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Azad A HaleemDepartment of Pediatrics, College of Medicine, University of Duhok, Duhok, Kurdistan, Iraq.

Azhar Alsaqee *Neonatology and Intensive Care Unit, College of Medicine, Hawler Medical University, Erbil, Kurdistan, Iraq.

Lana A Dizayi *College of Medicine, Salaheddin University, Erbil, Kurdistan, Iraq.

Sasan L Hanna *Department of Pediatrics, College of Medicine, Hawler Medical University, Erbil, Kurdistan, Iraq.

Abbas A Rabaty *Department of Pediatrics, College of Medicine, Hawler Medical University, Erbil, Kurdistan, Iraq.

Serdar Pedawi *Division of Pediatric Cardiology, Heevi Pediatric Teaching Hospital, Azadi Heart Center, Duhok, Kurdistan, Iraq.

Aso F Salih *Clinical Science Department, Children's Heart Hospital, College of Medicine, Sulaimani University, Sulaymaniyah, Kurdistan, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Without an available vaccine in Kurdistan, Respiratory Syncytial Virus (RSV) infection threatens younger children, burdens the healthcare system and contributes to household expenditure on health. Immunoprophylaxis remains the only preventive option in Kurdistan. Expert pediatricians recommend palivizumab to children at RSV risk; particularly infants (1) born within 29 gestational weeks and <1-year-old at RSV season start, (2) born premature (>29 gestational weeks) at risk for RSV hospitalization, (3) with congenital lung disease requiring oxygen therapy for >1 month and are <2 years old at RSV season start, and (4) with hemodynamically significant congenital heart disease and acyanotic heart and who are <2 years of age at RSV season start. We call onto health authorities to support palivizumab immunoprophylaxis to all children at risk for RSV.

Indexed as

immunoprophylaxisKurdistanpalivizumabpediatric respiratory carerespiratory syncytial virus

Identifiers

PMID40151184

DOI10.3389/fped.2025.1551734

PMCPMC11949000

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.